AGTR1 and acute coronary syndrome: From Figure 2, we could find the purified IgG type AT1-AAs (20 μg/mL) from 5 patients separately with acute coronary syndrome increased the beat rate 22 ± 5/min, compared with the control (exposed to the nonspecific IgG (nsIgG) from the same patients), and this effect could be abolished by both AT1 receptor blocker valsartan (1 μM) and overdose AT1-EC2 peptide (1 μg/mL), meaning AT1-AAs had an agonistic effects on AT1 receptor.